AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11153737 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive management strategy (routine early coronary angiography)
Number of subjects: 115
Study 11153737 — intervention group
Group type: COMPARATOR
Intervention: Conservative management strategy (noninvasive functional assessment)
Number of subjects: 115
Study 11153737 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive management strategy
Number of subjects: 115
Study 11153737 — intervention group
Group type: COMPARATOR
Intervention: Conservative management strategy
Number of subjects: 115
Study 11153737 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall event rates (death or recurrent nonfatal MI)
Number of subjects: 115
Study 9779901 — intervention group
Group type: EXPERIMENTAL
Intervention: Community re‐entry program
Number of subjects: 59
Study 9779901 — intervention group
Group type: COMPARATOR
Intervention: Occupational therapy
Number of subjects: 59
Study 8154016 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular artemether
Number of subjects: 0
Study 8154016 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular sulfadoxine-pyrimethamine
Number of subjects: 0
Study 3236376 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking videotape
Number of subjects: 77
Study 3236376 — intervention group
Group type: COMPARATOR
Intervention: Control videotape
Number of subjects: 77
Study 28803880 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (100,000 IU bolus followed by 4000 IU daily)
Number of subjects: 63
Study 28803880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 28803880 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 63
Study 26857762 — intervention group
Group type: EXPERIMENTAL
Intervention: Kernel bread (KB)
Number of subjects: 10
Study 26857762 — intervention group
Group type: COMPARATOR
Intervention: Control bread (CB)
Number of subjects: 10
Study 26857762 — intervention group
Group type: EXPERIMENTAL
Intervention: Both breads (CB and KB)
Number of subjects: 10
Study 25055933 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (50 μg every 4 h, maximum of 3 doses)
Number of subjects: 188
Study 25055933 — intervention group
Group type: COMPARATOR
Intervention: Intracervical dinoprostone (0.5 mg every 2 h, maximum of 2 doses)
Number of subjects: 188
Study 25055933 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol
Number of subjects: 188
Study 25055933 — intervention group
Group type: COMPARATOR
Intervention: Sublingual misoprostol and intracervical dinoprostone
Number of subjects: 188
Study 25055933 — intervention group
Group type: COMPARATOR
Intervention: Intracervical dinoprostone
Number of subjects: 188
Study 23381895 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Disc Replacement (TDR)
Number of subjects: 27
Study 23381895 — intervention group
Group type: COMPARATOR
Intervention: Monosegmental Fusion
Number of subjects: 27
Study 22151932 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignin peroxidase cream (LIP)
Number of subjects: 51
Study 22151932 — intervention group
Group type: COMPARATOR
Intervention: 2% hydroquinone cream
Number of subjects: 51
Study 22151932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 19187507 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment (Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14)
Number of subjects: 55
Study 19187507 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 55
Study 16720126 — intervention group
Group type: EXPERIMENTAL
Intervention: Stages of Change education approach
Number of subjects: 141
Study 16720126 — intervention group
Group type: COMPARATOR
Intervention: Usual care education approach
Number of subjects: 141
Study 15289368 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin 5000 IU daily
Number of subjects: 3706
Study 15289368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3706
Study 16206671 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrotalcite 1.0 g four times daily for 6 weeks
Number of subjects: 45
Study 16206671 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg twice daily for the first 2 weeks and 20 mg once daily for the following 4 weeks
Number of subjects: 45
Study 16206671 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrotalcite
Number of subjects: 45
Study 16206671 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole
Number of subjects: 45
Study 9738364 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen L-arginine 400 mg
Number of subjects: 70
Study 9738364 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 550 mg
Number of subjects: 70
Study 7834140 — intervention group
Group type: EXPERIMENTAL
Intervention: Community psychiatric nurse (CPN) care
Number of subjects: 0
Study 7834140 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention control group
Number of subjects: 0
Study 2468894 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 14
Study 2468894 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium (KCl, 20 mEq three times daily)
Number of subjects: 14
Study 2468894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2468894 — intervention group
Group type: COMPARATOR
Intervention: Calcium (Ca, 500 mg twice daily)
Number of subjects: 14
Study 2468894 — intervention group
Group type: COMPARATOR
Intervention: Digoxin (sodium‐potassium‐dependent ATPase inhibition)
Number of subjects: 14
Study 31826706 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure lists condition (six-word lists composed of words belonging to the same valence)
Number of subjects: 88
Study 31826706 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed lists condition (six-word lists composed of embedded neutral and emotional words)
Number of subjects: 88
Study 31332565 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% perfusion
Number of subjects: 20
Study 31332565 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% perfusion
Number of subjects: 20
Study 31332565 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% perfusion
Number of subjects: 20
Study 31332565 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathological assessment
Number of subjects: 20
Study 30239887 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cisplatin (HDC) - mean initial dose 100 mg/m2
Number of subjects: 2901
Study 30239887 — intervention group
Group type: COMPARATOR
Intervention: Low-dose cisplatin (LDC) - mean initial dose 40 mg/m2
Number of subjects: 2901
Study 28407271 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFNα‐2a
Number of subjects: 144
Study 28407271 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 144
Study 25907125 — intervention group
Group type: COMPARATOR
Intervention: Fried food consumption <1 per week
Number of subjects: 15362
Study 25907125 — intervention group
Group type: EXPERIMENTAL
Intervention: Fried food consumption 1 to 3 times per week
Number of subjects: 15362
Study 25907125 — intervention group
Group type: EXPERIMENTAL
Intervention: Fried food consumption 4 to 6 times per week
Number of subjects: 15362
Study 25907125 — intervention group
Group type: EXPERIMENTAL
Intervention: Fried food consumption 7 or more times per week
Number of subjects: 15362
Study 23891544 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (10-min lecture with supplementary materials)
Number of subjects: 203
Study 21665059 — intervention group
Group type: EXPERIMENTAL
Intervention: Support-person intervention (written materials plus three weekly telephone sessions lasting 10-30 minutes each)
Number of subjects: 534
Study 21665059 — intervention group
Group type: EXPERIMENTAL
Intervention: Support-person intervention
Number of subjects: 534
Study 21665059 — intervention group
Group type: COMPARATOR
Intervention: Control group (written materials)
Number of subjects: 534
Study 21665059 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 534
Study 19183504 — intervention group
Group type: EXPERIMENTAL
Intervention: Health and nutrition education intervention (two two-hour prenatal education sessions and four postpartum counseling visits)
Number of subjects: 302
Study 19183504 — intervention group
Group type: EXPERIMENTAL
Intervention: Health and nutrition education intervention
Number of subjects: 302
Study 19183504 — intervention group
Group type: COMPARATOR
Intervention: Usual health care during pregnancy and postpartum period (Control)
Number of subjects: 302
Study 16759587 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-measurement of capillary blood glucose (SMBG)
Number of subjects: 100
Study 16759587 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 100
Study 16759587 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet treatment
Number of subjects: 100
Study 16759587 — intervention group
Group type: EXPERIMENTAL
Intervention: Mathematical model for SMBG efficacy
Number of subjects: 100
Study 16759587 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC curve analysis
Number of subjects: 100
Study 15320990 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rev, tat, and nef intramuscularly at weeks 0, 4, and 16 at increasing doses (300, 900, and 1800 micrograms DNA)
Number of subjects: 15
Study 15320990 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 15
Study 15320990 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rev, tat, and nef intramuscularly
Number of subjects: 15
Study 15320990 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rev, tat, and nef in increasing doses
Number of subjects: 15
Study 15320990 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with comparable CD4 levels
Number of subjects: 15
Study 11131953 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert knowledge about behavioral psychology
Number of subjects: 0
Study 11131953 — intervention group
Group type: COMPARATOR
Intervention: Naive subjects
Number of subjects: 0
Study 9330391 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese herbal medicine (Juzentaihotou or Hotyuekkitou)
Number of subjects: 0
Study 9330391 — intervention group
Group type: COMPARATOR
Intervention: Control group (isolation only)
Number of subjects: 0
Study 1588377 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 70
Study 1588377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 3878905 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25(OH)2D3 treatment for a mean of 16.8 ± 6.4 months
Number of subjects: 42
Study 3878905 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 42
Study 31737366 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic endotracheal intubation (METI)
Number of subjects: 0
Study 31737366 — intervention group
Group type: COMPARATOR
Intervention: Classic endotracheal intubation (CETI)
Number of subjects: 0
Study 30365136 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated spinal manipulation
Number of subjects: 12
Study 30365136 — intervention group
Group type: COMPARATOR
Intervention: Simulated spinal mobilization
Number of subjects: 12
Study 25663254 — intervention group
Group type: EXPERIMENTAL
Intervention: VivaSight DLT
Number of subjects: 40
Study 25663254 — intervention group
Group type: COMPARATOR
Intervention: Conventional DLT
Number of subjects: 40
Study 24826396 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel ALA (5-aminolevulinic acid) treatment, 2 treatments 2 weeks apart
Number of subjects: 64
Study 24826396 — intervention group
Group type: COMPARATOR
Intervention: Observation (control)
Number of subjects: 64
Study 22938944 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty alone
Number of subjects: 63
Study 19390339 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Buddy telehealth communication device
Number of subjects: 13
Study 17465666 — intervention group
Group type: EXPERIMENTAL
Intervention: BAC-composite with 0.25% BAC
Number of subjects: 0
Study 17465666 — intervention group
Group type: EXPERIMENTAL
Intervention: BAC-composite with 0.75% BAC
Number of subjects: 0
Study 17465666 — intervention group
Group type: EXPERIMENTAL
Intervention: BAC-composite with 1.25% BAC
Number of subjects: 0
Study 17465666 — intervention group
Group type: EXPERIMENTAL
Intervention: BAC-composite with 1.75% BAC
Number of subjects: 0
Study 17465666 — intervention group
Group type: EXPERIMENTAL
Intervention: BAC-composite with 2.5% BAC
Number of subjects: 0
Study 17465666 — intervention group
Group type: EXPERIMENTAL
Intervention: BAC-composite with 5% BAC
Number of subjects: 0
Study 17465666 — intervention group
Group type: COMPARATOR
Intervention: Control composite (no BAC)
Number of subjects: 0
Study 16081585 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (oral, 10 mg/day) combined with inhaled Budesonide (400 microg/bid)
Number of subjects: 40
Study 16081585 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (400 microg/bid)
Number of subjects: 40
Study 12069111 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant therapy based on idebenone
Number of subjects: 0
Study 12069111 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 plus Vitamin E administration
Number of subjects: 0
Study 12069111 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 9578859 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual breast screening invitation accompanied by a self administered questionnaire
Number of subjects: 6400
Study 9578859 — intervention group
Group type: COMPARATOR
Intervention: Usual breast screening invitation alone
Number of subjects: 6400
Study 10560070 — intervention group
Group type: EXPERIMENTAL
Intervention: Water volumetry
Number of subjects: 29
Study 10560070 — intervention group
Group type: EXPERIMENTAL
Intervention: Figure of eight method
Number of subjects: 29
Study 1804010 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime (2.0 g intravenously twice daily for 4 to 28 days)
Number of subjects: 79
Study 1804010 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime (2.0 g every 8 h)
Number of subjects: 79
Study 6228347 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ipratropium
Number of subjects: 34
Study 6228347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 31496381 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided quadratus lumborum block (QLB) with 10 ml of 0.5% bupivacaine and 10 ml of 2% lidocaine before ESWL
Number of subjects: 40
Study 31496381 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided quadratus lumborum block (QLB)
Number of subjects: 40
Study 31496381 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 29087444 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative maneuvers applied for the duration of the entire surgical procedure (group 2)
Number of subjects: 122
Study 29087444 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative and intraoperative measures taken (group 3)
Number of subjects: 122
Study 29087444 — intervention group
Group type: COMPARATOR
Intervention: No protective measures taken (group 1)
Number of subjects: 122
Study 26444149 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 μg.kg(‐1) dexmedetomidine
Number of subjects: 100
Study 26444149 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg.kg(‐1) propofol
Number of subjects: 100
Study 26444149 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9% (Control)
Number of subjects: 100
Study 24857264 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency (10 Hz) rTMS
Number of subjects: 36
Study 24857264 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 36
Study 22337531 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS (n=117)
Number of subjects: 236
Study 22337531 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS (n=119)
Number of subjects: 236
Study 20516229 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task condition with spatially incompatible stimulus‐response mapping
Number of subjects: 0
Study 20516229 — intervention group
Group type: COMPARATOR
Intervention: Single-task conditions (saccade or manual response)
Number of subjects: 0
Study 18937112 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (Rebif 44 microg)
Number of subjects: 16
Study 18937112 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 16
Study 15794869 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral chlorambucil at a dose of 8 mg/m² (6 mg/m² for those > 75 years of age) for 10 days every 28 days to a maximum of 12 cycles
Number of subjects: 143
Study 15794869 — intervention group
Group type: COMPARATOR
Intervention: Oral or intravenous (I.V.) fludarabine at a dose of 40 mg/m² orally or 25 mg/m² I.V. (30 mg/m² orally or 20 mg/m² I.V. for those > 75 years of age) for 5 days every 28 days to a maximum of 6 cycles
Number of subjects: 143
Study 12872394 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone inhalation combined with XQLD
Number of subjects: 54
Study 12872394 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone inhalation
Number of subjects: 54
Study 12872394 — intervention group
Group type: COMPARATOR
Intervention: XQLD
Number of subjects: 54
Study 12872394 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 54
Study 10697624 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha alone
Number of subjects: 18
Study 10697624 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha plus vinblastine
Number of subjects: 18
Study 10697624 — intervention group
Group type: COMPARATOR
Intervention: Surgery only (Control)
Number of subjects: 18
Study 9160568 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous caffeine (3, 5, and 7 mg/kg)
Number of subjects: 30
Study 9160568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2690914 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluorouracil 500 mg, methotrexate 25 mg and chlorambucil 10 mg p.o. on day 1 and fluorouracil 500 mg and chlorambucil 10 mg p.o. on day 2 (LMF) every 21 days for eight cycles.
Number of subjects: 574
Study 2690914 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 574
Study 971343 — intervention group
Group type: EXPERIMENTAL
Intervention: Secholex (15 g/day)
Number of subjects: 46
Study 971343 — intervention group
Group type: COMPARATOR
Intervention: Cholestyramine (16 g/day)
Number of subjects: 46
Study 971343 — intervention group
Group type: EXPERIMENTAL
Intervention: Secholex (9 g/day)
Number of subjects: 46
Study 30198198 — intervention group
Group type: EXPERIMENTAL
Intervention: Mr. Lonely PSA (portrayed outdoor activity as not normative)
Number of subjects: 333
Study 30198198 — intervention group
Group type: COMPARATOR
Intervention: Control message (VERB PSA, portrayed outdoor activity as the norm)
Number of subjects: 333
Study 28533305 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ART
Number of subjects: 4685
Study 28533305 — intervention group
Group type: COMPARATOR
Intervention: Deferred ART
Number of subjects: 4685
Study 25781384 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 5 mg IV
Number of subjects: 213
Study 25781384 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline IV)
Number of subjects: 213
Study 23062733 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen-thawed embryo transfers
Number of subjects: 186
Study 23062733 — intervention group
Group type: COMPARATOR
Intervention: Fresh embryo transfers
Number of subjects: 186
Study 21139446 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy intervention program (DVD, healthcare booklet, support groups, medical follow-ups)
Number of subjects: 60
Study 21139446 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy intervention program
Number of subjects: 60
Study 21139446 — intervention group
Group type: COMPARATOR
Intervention: Conventional health education (control group)
Number of subjects: 60
Study 18160498 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee replacement with patellar resurfacing
Number of subjects: 142
Study 18160498 — intervention group
Group type: COMPARATOR
Intervention: Total knee replacement without patellar resurfacing
Number of subjects: 142
Study 16365070 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified wheat bread
Number of subjects: 41
Study 16365070 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified rye bread
Number of subjects: 41
Study 16365070 — intervention group
Group type: COMPARATOR
Intervention: Regular wheat bread (control)
Number of subjects: 41
Study 16365070 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular wheat bread and cholecalciferol supplement (vitamin D control)
Number of subjects: 41
Study 15490769 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 0
Study 15490769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10827226 — intervention group
Group type: EXPERIMENTAL
Intervention: MARS treatment in addition to hemodiafiltration (HDF) and standard medical therapy
Number of subjects: 13
Study 10827226 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (HDF and standard medical treatment alone)
Number of subjects: 13
Study 8770960 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraphysiologic dose B-vitamin supplementation (15 mg folic acid/day, 100 mg B-6/day, 1 mg B-12/day)
Number of subjects: 27
Study 8770960 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (1 mg folic acid, 10 mg B-6, 12 micrograms B-12)
Number of subjects: 27
Study 8770960 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraphysiologic dose B-vitamin supplementation
Number of subjects: 27
Study 1608903 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 ml of alcohol (94%) in 75 ml of orange juice
Number of subjects: 10
Study 1608903 — intervention group
Group type: COMPARATOR
Intervention: 150 ml of orange juice
Number of subjects: 10
Study 3885701 — intervention group
Group type: COMPARATOR
Intervention: 100 mg chlorthalidone
Number of subjects: 140
Study 3885701 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg chlorthalidone
Number of subjects: 140
Study 28393552 — intervention group
Group type: EXPERIMENTAL
Intervention: Concern about falling outdoors
Number of subjects: 120